Filtered By:
Condition: Ventricular Tachycardia
Drug: Amiodarone

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Main determinants of physician-driven amiodarone discontinuation in clinical practice
ConclusionStudy showed that within the first two years of treatment, despite persistent indication, amiodarone was discontinued in 1 out of 10 patients in the absence of side effects, mostly in younger patients with less comorbidities, which may not always be justified. There is a need for qualitative research to elucidate the reasons for such physicians ’ decisions. Table.Multivariable Cox Proportional HAZARD Regression analysis of permanent Amiodarone discontinuation due to physician decisionVariableHR95% CIP valueAge0.9700.95-0.990.003VT/VF/electrical storm0.1390.04-0.450.001VKA therapy0.5980.38-0.940.026Ablation of A...
Source: Europace - May 24, 2021 Category: Cardiology Source Type: research

Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients
Publication date: Available online 13 February 2017 Source:Journal of Clinical Neuroscience Author(s): Michael Su, David Seki, Asma M. Moheet Neurological injury is often associated with cardiac abnormalities, including electrophysiological issues. Cardioversion of acute atrial fibrillation (<48h’ duration) without anticoagulation carries about a 0.7% risk of thromboembolism. There is limited data on managing acute atrial fibrillation specifically in the neuroscience intensive care unit (NSICU) setting. We sought to determine the safety of using intravenous (IV) amiodarone for restoring sinus rhythm in patients w...
Source: Journal of Clinical Neuroscience - February 13, 2017 Category: Neuroscience Source Type: research